CA125 dominated performance for ovarian cancer early detection among four serum biomarkers evaluated in EPIC study prediagnostic serum, rising on average 3 years prior to detection. Adding HE4 provided only marginal improvement. This natural history supports annual testing for early detection and highlights the importance of biomarker discovery complementing CA125. Clin Cancer Res; 22(18); 4542–4. ©2016 AACR.
See related article by Terry et al., p. 4664
- Received July 1, 2016.
- Accepted July 7, 2016.
- ©2016 American Association for Cancer Research.